StemPar Sciences Secures Initial Funding For Its Novel Cancer Metabolism Drugs

Published: Jan 02, 2013

San Francisco, CA, Jan. 2, 2013 (GLOBE NEWSWIRE) -- Privately held StemPar Sciences, Inc. today announced an initial investment from Troika Venture Capital, a multi-profile international venture capital firm. In addition, Troika has committed to participate in future StemPar financings.

Back to news